Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 184 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antimicrobial Effectiveness Clear all
Not listed Phase 3 Interventional

Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

NCT02901717
View directory record Official record
Conditions
Catheter-related Infections
Interventions
Mino-Lok, Antibiotic lock
Drug
Lead sponsor
Leonard-Meron Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Hines, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa

NCT00304187
View directory record Official record
Conditions
Bulimia Nervosa, Eating Disorders
Interventions
Erythromycin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)

NCT03366207
View directory record Official record
Conditions
UTI - Lower Urinary Tract Infection, Antibiotic Resistant Infection
Interventions
Ciprofloxacin
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

NCT01701401
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

NCT03824795
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
MGB-BP-3
Drug
Lead sponsor
MGB Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Miami, Florida • Orlando, Florida • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 4 Interventional

Staph Intervention for Effective Local Defense

NCT06210594
View directory record Official record
Conditions
Staphylococcus Aureus Infection
Interventions
Mupirocin + Nozin + chlorhexidine gluconate, Education + Household supplies
Combination Product · Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

NCT00002431
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
13 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

Efficacy Study of a Bioelectric Dressing to Treat Wounds Caused by Curettage and Electrodesiccation

NCT01004055
View directory record Official record
Conditions
Wound Healing, Wound Infection
Interventions
Procellera™ Antimicrobial Wound Dressing, ACTICOAT™ Antimicrobial Barrier Dressing, Mepilex® Ag Silver Foam Dressing
Device · Drug
Lead sponsor
Vomaris Innovations
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Oro Valley, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2009 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

NCT03038178
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Interventions
LAI plus multi-drug regimen
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation

NCT03224299
View directory record Official record
Conditions
Preoperative Skin Preparation
Interventions
OCT - clear, OCT- tinted, ChloraPrep, Saline
Drug · Other
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Bozeman, Montana • Butte, Montana
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers

NCT01531699
View directory record Official record
Conditions
Infection Secondary to Surgical Procedure
Interventions
ALT005 Ophthalmic Prep Solution, saline control, Betadine ophthalmic prep solution
Drug · Other
Lead sponsor
Altacor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 3, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Safety and Effectiveness of Octenidine Dihydrochloride

NCT03140254
View directory record Official record
Conditions
Preoperative Skin Preparation
Interventions
Chlorhexidine gluconate, N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride, Placebo
Drug
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

Acute Otitis Media (AOM) Therapy Trial in Young Children

NCT00377260
View directory record Official record
Conditions
Acute Otitis Media
Interventions
amoxicillin-clavulanate, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 23 Months
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 3, 2026, 5:43 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Nutraceutical Efficacy for rUTI

NCT03395288
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
D-Mannose
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 3, 2026, 5:43 AM EDT
Terminated Phase 3 Interventional Results available

CleanUP IPF for the Pulmonary Trials Cooperative

NCT02759120
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Antimicrobial therapy: Co-trimoxazole or Doxycycline, No Intervention: Standard of Care
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 4 Interventional

Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients

NCT00410527
View directory record Official record
Conditions
Bacterial Infections
Interventions
Merrem
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

NCT02525523
View directory record Official record
Conditions
Pouchitis
Interventions
Alicaforsen, Placebo
Drug
Lead sponsor
Atlantic Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 1 Interventional Results available

Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis

NCT01169038
View directory record Official record
Conditions
Pulmonary Sarcoidosis, Lung Function
Interventions
levaquin; ethambutol; rifampin and azithromycin.
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 3, 2026, 5:43 AM EDT
Terminated Phase 3 Interventional Results available

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

NCT02015637
View directory record Official record
Conditions
Gonorrhea
Interventions
Delafloxacin, Ceftriaxone
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
25
States / cities
Birmingham, Alabama • Chula Vista, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections

NCT00921024
View directory record Official record
Conditions
Complicated Urinary Tract Infection
Interventions
CXA-101, Ceftazidime
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 90 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Los Angeles, California • Orlando, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 3, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?

NCT06810687
View directory record Official record
Conditions
Urinary Tract Infection (Diagnosis)
Interventions
Methenamine Hippurate 1g BD, Antibiotic prophylaxis
Drug · Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 3, 2026, 5:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 3, 2026, 5:43 AM EDT